Loss of GPRC5D enhances the proliferative capacity and competitive fitness of myeloma upon anti-GPRC5D immunotherapy.

Munawar U, Thurner J, Nerreter S, Nerreter T, Leipold AM, Han S, Verbruggen C, Gerhard-Hartmann E, Vogt C, Grams B, Kurian S, Besant E, Roth S, Weingart J, Eiring P, Truger M, Afrin N, Steinbrunn T, Tamamushi Y, Zhou X, Rein N, Lehmann J, Köppel M, Rosenwald A, Haferlach C, Hudecek M, Saliba AE, Rasche L, Sauer M, Einsele H, Kuster B, Waldschmidt J, Kortüm KM

Open source

DOI: 10.1038/s41375-026-02920-7
Published: 2026 Jun
Container: Leukemia
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41375-026-02920-7,
  title = {Loss of GPRC5D enhances the proliferative capacity and competitive fitness of myeloma upon anti-GPRC5D immunotherapy.},
  author = {Munawar U and Thurner J and Nerreter S and Nerreter T and Leipold AM and Han S and Verbruggen C and Gerhard-Hartmann E and Vogt C and Grams B and Kurian S and Besant E and Roth S and Weingart J and Eiring P and Truger M and Afrin N and Steinbrunn T and Tamamushi Y and Zhou X and Rein N and Lehmann J and Köppel M and Rosenwald A and Haferlach C and Hudecek M and Saliba AE and Rasche L and Sauer M and Einsele H and Kuster B and Waldschmidt J and Kortüm KM},
  year = {2026},
  journal = {Leukemia},
  doi = {10.1038/s41375-026-02920-7},
  url = {https://doi.org/10.1038/s41375-026-02920-7}
}

RIS

TY  - JOUR
TI  - Loss of GPRC5D enhances the proliferative capacity and competitive fitness of myeloma upon anti-GPRC5D immunotherapy.
AU  - Munawar U
AU  - Thurner J
AU  - Nerreter S
AU  - Nerreter T
AU  - Leipold AM
AU  - Han S
AU  - Verbruggen C
AU  - Gerhard-Hartmann E
AU  - Vogt C
AU  - Grams B
AU  - Kurian S
AU  - Besant E
AU  - Roth S
AU  - Weingart J
AU  - Eiring P
AU  - Truger M
AU  - Afrin N
AU  - Steinbrunn T
AU  - Tamamushi Y
AU  - Zhou X
AU  - Rein N
AU  - Lehmann J
AU  - Köppel M
AU  - Rosenwald A
AU  - Haferlach C
AU  - Hudecek M
AU  - Saliba AE
AU  - Rasche L
AU  - Sauer M
AU  - Einsele H
AU  - Kuster B
AU  - Waldschmidt J
AU  - Kortüm KM
PY  - 2026
JO  - Leukemia
DO  - 10.1038/s41375-026-02920-7
UR  - https://doi.org/10.1038/s41375-026-02920-7
ER  -

APA

U, M., J, T., S, N., T, N., AM, L., S, H., C, V., E, G., C, V., B, G., S, K., E, B., S, R., J, W., P, E., M, T., N, A., T, S., Y, T., X, Z., N, R., J, L., M, K., A, R., C, H., M, H., AE, S., L, R., M, S., H, E., B, K., J, W., & KM, K. (2026). Loss of GPRC5D enhances the proliferative capacity and competitive fitness of myeloma upon anti-GPRC5D immunotherapy.. Leukemia. https://doi.org/10.1038/s41375-026-02920-7

Source records

pubmed · retrieved 2026-09-25T18:36:42.340Z
europe-pmc · retrieved 2026-09-25T18:36:42.308Z